u n d e r a p p r e c i a t e d m a n i f e s t a t i o n s o f M A S s u c h a s h e p a t o b i l i a r y
Tor contributing to the dcvclopmcnt of this genetically heterogeneous disorder. disease a n d early d e a t h , identification of constitutively activating Gmctic studies of early-onset NIDDM havc provided a bcuer understanding of i u mutations of Gs-a as the cause of most if not all of the manifestations c a u s e s a n d have pointed to cellular pathways that arc important for the maintenance of glucose homeostasis and whose pcaurbation may conlrihutc to the o f M A S h a s i m p o r t a n t i m p l i c a t i o n s f o r o u r u n d e r s t a n d i n g o f cAM1' dcvclonmcnt of the morc common lac-onset forms of NIDDM. r e g u l a t i o n o f c e l l f u n c t i o n , a n d ultinlately, f o r t r e a t m e n t o f M A S .
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Stanford University, Stanford, CA 94305, USA Growth hormone inscnsilivity syndrome (CHIS or Laron syndrome) is an aulosomal recessive disorder caused by mutations in rhc gene for the growth hormone receptor (GHR). This genc, located on chromosome region 5p13.1-p12 ( I ) encodes a 6 2 0 amino acid protcin with a ccntrally located hydrophobic transmembrane d o m a~n .
Proteolytic cleavage of the cxtracellular domain that includes the growth hormone bind~ng s~t e gcncratcs the circulating GHBP. One G H molecule binds to two GHBP molecule resulting in dimcrizat~on of the receptors, possibly an esscntlal step for signal transduct~on.
In order to detect GHR mut;~tions In p;~ticnts wtth C H I S , a screening procedure has been devised (2.3). All nlnc cxons and s u r r o u n d~n g splice junctions of the G H R gene are amplifted by PCR w~t h p r~m c r s d c s~g n c d from the published sequence. Each PCR product IS analysed for altered ~nelting behavior by denaturing gradient gel clcctrophoresis (DGGE). A GC-clamp is added to one primer to ensurc complete analys~s 01' the cntlrc exon and splice site regions. PCR products that arc positlvc by DGGE scrccnlng arc sequenced either directly or after subcloning. In our laboratory, Dr. Mary Anne Berg has identified two nonsense mutations (R43X arid R217X). two splice lunction mutations (189-1 G-to-T and 71+1 G-to-A) and two l'rameshift mutations leading to translational stop codons (46 dcl TT and 230 del T A ) all of which involve either exon 4 or exon 7 (3). The niost t~nusual mutation -that she has detected in over 5 0 affectcd ~ndividuals from Ecuador -involves a single nucleotide substitution in codon I80 that doca not change the amino acid encoded (EISOE). Thc A-to-G transvcrslon, however, creates a new 5' spllcc site which is exclusively uscd and lcads to am in-frame dcletion 01 24 nucleotidcs from exon 6 in the patients' niRNA (2). Since the G H b~n d l n g and rcccptor dimerizat~on sites would rernaln intact hut no response to G H has hccn rcportcd in these paticnts, the mutant rcccptor protcln is poalulatcd to undergo abnornial folding and intracellular dcgradatlon. The EIXOspIlcc mutation has not been derected in any pattents outside of Ecuador
In general, the mutations arc unique to parttculatr l a n i~l~c s or gcograph~c areas. Only R43X has recurred on d~ilcrent haplotype hackgrounds. 
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Medical Institute, University of Chicago, Chicago, 1L 60637, USA NIDDM is one of the most common metabolic diseases affecting -5% of the world population. Howcvcr despite much research, the genetic and nongcnetic I'ac~ors that conlrihuu: to its dcvelopmcnt rcmllin largely unknown. Careful clinical studies of subjects with NIDDM whose onset occurred during childhood or adolcsccncc havc idcntilicd a Familial form of diabctes termed maturity-onset diabetes of the young or MODY. Its carly age of onsct, autosomal dominant mode of inheritance and availability of multigenerational pcdigrces make MODY an attractive model for identifying diabctcs-susceptibility genes using gcnctlc Fetal growth (FG) in late gestation (LG) is primarily determined by uteroplacental transfer of nutrients. FG is normally constrained by the capacity of this transfer. In LG, fetal IGF-I is acutely regulated by glucose, but not by amino acid availabtltty, acting via enhanced insulin release; this provides the mechanism of fetal overgrowth induced by hyperinsulinism. Fetal IGF-I levels correlate with fetal nutritional status and thus FG. Direct evidence for the role of IGF-1 in FG is provided by embryo transfer experiments in mice selected for high or low IGF-l levels. The infusion of IGF-I (60~glkglhr) to LG fetal sheep increased IGF-I 4 fold without a measurable change in fetal or placental glucose uptake. However placental lactate production fell (~1 0 . 0 3 ) . The amino-nitrogen concentration fell (p <0.01) in both mother and fetus as did fetal urea production (J <0.05). These observations suggest that IGF-I inhihits fetal protein catabolism, promotes fetal anabolism, enhances placental amino acid transfer and alters placental metabolism favourably. It is suggested that glucose availability affects tetal IGF-I production via altered insulin secretion and this in turn has anabolic and anticatabolic consequences. IGF binding proteins are also acutely modulated hy nutrient availability. Fetal IGF-2 in late gestation is under lesser nutritional regulation compatible with a more constitutive role in the regulation of FG. Maternal IGF-l administration throughout pregnancy in rodents abolishes the physiological constrilints on FG without affecting placental growth. Maternal IGF-I administration reduces fetal urea production in sheep. It is suggestd that maternal IGF-1,under nutr~tion;~l and hormonal control.determines nutrient availability and transfer across the placenta Thus optimal FG depends on coordinate increases in both feral and maternal IGF-I 
